OXiGENE Inc  

(Public, NASDAQ:OXGN)   Watch this stock  
Find more results for OXGN
0.597
-0.003 (-0.50%)
Real-time:   12:30PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.57 - 0.60
52 week 0.49 - 1.68
Open 0.60
Vol / Avg. 59,823.00/207,391.00
Mkt cap 15.98M
P/E     -
Div/yield     -
EPS -0.54
Shares 26.54M
Beta 2.38
Inst. own 9%
Apr 29, 2016
Q1 2016 OXiGENE Inc Earnings Release (Estimated)
Mar 28, 2016
Q4 2015 OXiGENE Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -54.68% -47.18%
Return on average equity -58.50% -50.24%
Employees 13 -
CDP Score - -

Address

701 Gateway Blvd Ste 210
SOUTH SAN FRANCISCO, CA 94080-7041
United States - Map
+1-650-6357000 (Phone)
+1-650-6357001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OXiGENE, Inc. is a biopharmaceutical company primarily focused on the development of vascular disrupting agents (VDAs), for the treatment of cancer. The Company has two clinical-stage product candidates. The Company is testing its lead compound fosbretabulin tromethamine (fosbretabulin) in two indications, recurrent ovarian cancer and gastrointestinal neuroendocrine tumors (GI-NETs). The Company is testing its second compound, OXi4503, in patients with relapsed or refractory acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). The Company's product fosbretabulin is a small molecule, reversible inhibitor of tubulin polymerization. Similar to fosbretabulin, OXi4503 is a small molecule reversible inhibitor of tubulin polymerization. Additionally, orthoquinone metabolite, which is formed via oxidation, has anti-proliferative effect on leukemic cells.

Officers and directors

Frederick W. Driscoll Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
William D. Schwieterman M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Matthew M. Loar CPA Chief Financial Officer, Principal Accounting Officer
Age: 51
Bio & Compensation  - Reuters
David Chaplin Ph.D. Chief Scientific Officer, Director
Age: 59
Bio & Compensation  - Reuters
Simon C. Pedder Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
Tamar D. Howson Independent Director
Age: 67
Bio & Compensation  - Reuters
Gerald McMahon Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters